[The use of TruCare III insulin pump in patients with type 1 diabetes mellitus].

Abstract

The development of devices for continuous subcutaneous insulin infusion (CSII or insulin pumps) dramatically improved medical care for patients with diabetes mellitus. Insulin pump production widens annually resulting in number of new models entering the market, that differs in price but are similar in technical features. The entering of such new models to the Russian market can cause practical issues both in patient and in health care provider, so their estimation is of great importance. Insulin pump TruCare III (Apex Medical Co., Ltd, China) was registered in Russian Federation in September 15, 2023. The clinical experience of the TruCare III use in patients with type 1 diabetes mellitus is presented with the focus on glycemic parameters and custom features.